Market Overview - Hong Kong stocks opened high but closed lower, with the Hang Seng Index, the China Enterprises Index, and the Hang Seng Tech Index falling by 0.1% to 0.2%[1] - Major tech stocks like Alibaba (9988 HK), NetEase (9999 HK), and Meituan (3690 HK) declined, while NIO (09866) saw a significant rise of 14.1% after reporting a profitable quarter[1] - The Dow Jones and S&P 500 in the US fell by 0.6% and 0.1%, respectively, while the Nasdaq rose by 0.1%[2] Economic Indicators - The US February CPI rose by 2.4%, aligning with Bloomberg's forecast and previous values[3] - US crude oil inventories were reported at 3.824 million barrels, exceeding the forecast of 2.8 million barrels and higher than the previous value of 3.475 million barrels[3] Sector Performance - The healthcare sector in Hong Kong saw a decline of 1.1%, but companies like Qianxin Biotech (2509 HK) and Junshi Biosciences (1877 HK) experienced stock price increases of 4.9% and 0.2%, respectively, due to positive news on product approvals[4] - The renewable energy and utilities sector performed well, with stocks like Xinyi Solar (968 HK) and Longyuan Power (916 HK) rising between 3.7% and 6.8%[5] - The automotive sector was led by CATL (3750 HK), which rose by 9% following strong earnings, and Geely (175 HK), which increased by 8.2% ahead of a technology launch[5]

Core Viewpoint - Junshi Bioscience has announced adjustments to certain sub-projects and funding amounts related to its fundraising initiatives, maintaining the total amount of raised funds unchanged [1][3]. Fundraising and Project Adjustments - The company held board and supervisory meetings on May 29, 2025, to approve changes to the "Innovative Drug R&D Project" under the 2022 fundraising efforts, specifically adjusting clinical trial sub-projects and their funding amounts [1]. - New sub-projects added include "JS207 domestic and international R&D," "JS107 domestic and international R&D," "JS125 domestic and international R&D," "JT002 domestic and international R&D," "JS203 domestic and international R&D," and "JS015 domestic and international R&D," with funding sourced from reduced amounts in other sub-projects [2]. Strategic Rationale - The adjustments are based on the company's development strategy and product R&D progress, aimed at improving the efficiency of fund utilization and optimizing resource allocation, thereby supporting long-term development [3]. - The changes will not adversely affect the company's normal operations and align with the long-term interests of all shareholders [3]. Fundraising Details - In 2022, Junshi Bioscience raised a total of RMB 3.7765 billion by issuing 70 million A-shares at a price of RMB 53.95 per share, with a net amount of RMB 3.7448 billion after deducting issuance costs [4]. - The funds were deposited into a special account for fundraising and were verified by a certified public accountant [4]. Company Performance - Since its listing on July 15, 2020, Junshi Bioscience has raised a total of RMB 8.613 billion through two fundraising rounds [7]. - The company reported a net profit attributable to shareholders of -2.35 billion in Q1 2025, an improvement from -2.83 billion in the same period last year, with a revenue of 5.01 billion, reflecting a year-on-year growth of 31.46% [7][8].